Bd initiates international study to expand treatment options for patients with peripheral arterial disease

First patient enrollment in agility study begins investigations of safety and effectiveness of bd vascular covered stent for treatment of pad franklin lakes, n.j. , march 4, 2024 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced the enrollment of the first patient in the investigational device exemption (ide) study, "agility," which will assess the safety and effectiveness of the bd vascular covered stent for the treatment of peripheral arterial disease (pad).
BDX Ratings Summary
BDX Quant Ranking